

# Summary of results for people diagnosed with exocrine pancreatic cancer (ICD-10 code C25.0) in England (2021-22) and in Wales (2022-23).

## Diagnosis and staging

**17,328**

diagnoses of pancreatic cancer in England in 2021-22

**926**

diagnoses of pancreatic cancer in Wales in 2022-23

England

51% Men  
50% Women


Wales

50% Men  
50% Women

**74**  
years

Median age at diagnosis (England and Wales)

### Stage at diagnosis\*




## Work up and waiting times



**76%**


of people had a record of an Multi-Disciplinary Team discussion in England.

### Median waiting times\*\* (IQR\*\*\* )



## Treatment

### Percentage of people receiving any form of disease-targeted treatment



65 % (England) and 60% (Wales) of people with performance status 0-2 (stage 1-3) received any form of disease-targeted treatment

## Supportive care



**54%**

of people diagnosed during 2020-21 in England were prescribed PERT in primary care. Note: more likely to be prescribed PERT if receiving disease-targeted treatment (84% vs 38%)




**87%**

of people with new diagnoses of pancreatic cancer were seen by a Clinical Nurse Specialist in England\*\*\*\*

## Survival

### Percentage of people who survived for 30 days or 1 year after diagnosis in England and Wales.



\* Based on people with complete staging information available

\*\* The figure is based on people diagnosed after GP referral in both England and Wales

\*\*\* Interquartile range - a measure of the spread of the results. It demonstrates the difference between the first quartile (lower 25%) and the third quartile (upper 25%) of results.

\*\*\*\* Information missing for 48% of people